Annual Revenue Comparison: BioMarin Pharmaceutical Inc. vs Sarepta Therapeutics, Inc.

A Decade of Growth: BioMarin vs. Sarepta

In the competitive landscape of biotechnology, BioMarin Pharmaceutical Inc. and Sarepta Therapeutics, Inc. have showcased remarkable revenue trajectories over the past decade. From 2014 to 2023, BioMarin's revenue surged by over 220%, reflecting its robust pipeline and strategic market positioning. In contrast, Sarepta, while starting from a modest base, exhibited an impressive growth rate of over 12,600%, underscoring its rapid expansion and innovation in genetic medicine.

Key Insights

• BioMarin's Steady Climb: Starting at approximately $751 million in 2014, BioMarin's revenue reached nearly $2.42 billion by 2023, highlighting consistent growth.
• Sarepta's Meteoric Rise: From a mere $9.76 million in 2014, Sarepta's revenue skyrocketed to $1.24 billion in 2023, driven by breakthroughs in muscular dystrophy treatments.

This comparison not only illustrates the dynamic nature of the biotech sector but also emphasizes the potential for transformative growth through innovation.